Sermorelin vs Tesamorelin
Side-by-Side Comparison
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of... |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Previously FDA-approved (Geref, discontinued); now used off-label via compounding | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Safety Profile | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) | Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%); Headache, nausea, and flu-like symptoms reported |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 100–300 mcg/day SC | 2 mg/day SC (FDA-approved dose) |
| Frequency | Once daily (typically before bed) | Once daily |
| Molecular Weight | ~3357.9 g/mol | ~5135.9 g/mol |
| Half-Life | ~10–20 minutes | ~26–38 minutes |
Overview
Sermorelin and Tesamorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Tesamorelin — Mechanism & Evidence
Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) and the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed as Egrifta. It stimulates endogenous GH and IGF-1 production. Egrifta WR, a new weekly-reconstitution formulation, was FDA-approved in March 2025. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Shared Research Applications
Both peptides are studied for: Body Composition.
Sermorelin is also researched for: Anti-Aging, Sleep.
Tesamorelin is also researched for: no additional unique applications.
Safety Considerations
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Tesamorelin: Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%) Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics
Related Products
Sermorelin 5mg
5mg
Tesamorelin 10mg
10mg
Related Research News
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
Synergistic Growth Hormone Effects of Sermorelin and Ipamorelin Blend
Research peptides Sermorelin and Ipamorelin may work together to boost growth hormone release from pituitary cells through distinct pathways. Sermorelin mimics the active part of natural GHRH, while Ipamorelin targets GHS-R1a receptors selectively. Laboratory studies indicate this combination could produce higher hGH peaks than either alone, with potential anabolic benefits via IGF-1.
Why Research Peptides Vary in Price: Manufacturing Complexity Breakdown
Research peptides show wide price differences per mg, such as GHK-Cu being cheaper than retatrutide or BPC-157 less costly than tesamorelin. These variations stem from manufacturing challenges in solid-phase peptide synthesis, including sequence length, modifications, and purification needs. Understanding these factors helps researchers assess value across suppliers.